A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)

Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain famil...

Descripción completa

Detalles Bibliográficos
Autores principales: Viúdez, Antonio, Carvalho, Filipe L.F., Maleki, Zahra, Zahurak, Marianna, Laheru, Daniel, Stark, Alejandro, Azad, Nilofer Z., Wolfgang, Christopher L., Baylin, Stephen, Herman, James G., De Jesus-Acosta, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Papers: Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041882/
https://www.ncbi.nlm.nih.gov/pubmed/26894863
http://dx.doi.org/10.18632/oncotarget.7436
_version_ 1782456499463782400
author Viúdez, Antonio
Carvalho, Filipe L.F.
Maleki, Zahra
Zahurak, Marianna
Laheru, Daniel
Stark, Alejandro
Azad, Nilofer Z.
Wolfgang, Christopher L.
Baylin, Stephen
Herman, James G.
De Jesus-Acosta, Ana
author_facet Viúdez, Antonio
Carvalho, Filipe L.F.
Maleki, Zahra
Zahurak, Marianna
Laheru, Daniel
Stark, Alejandro
Azad, Nilofer Z.
Wolfgang, Christopher L.
Baylin, Stephen
Herman, James G.
De Jesus-Acosta, Ana
author_sort Viúdez, Antonio
collection PubMed
description Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET.
format Online
Article
Text
id pubmed-5041882
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-50418822016-10-10 A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET) Viúdez, Antonio Carvalho, Filipe L.F. Maleki, Zahra Zahurak, Marianna Laheru, Daniel Stark, Alejandro Azad, Nilofer Z. Wolfgang, Christopher L. Baylin, Stephen Herman, James G. De Jesus-Acosta, Ana Oncotarget Research Papers: Pathology Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET. Impact Journals LLC 2016-02-17 /pmc/articles/PMC5041882/ /pubmed/26894863 http://dx.doi.org/10.18632/oncotarget.7436 Text en Copyright: © 2016 Viúdez et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Papers: Pathology
Viúdez, Antonio
Carvalho, Filipe L.F.
Maleki, Zahra
Zahurak, Marianna
Laheru, Daniel
Stark, Alejandro
Azad, Nilofer Z.
Wolfgang, Christopher L.
Baylin, Stephen
Herman, James G.
De Jesus-Acosta, Ana
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title_full A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title_fullStr A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title_full_unstemmed A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title_short A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
title_sort new immunohistochemistry prognostic score (ips) for recurrence and survival in resected pancreatic neuroendocrine tumors (pannet)
topic Research Papers: Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041882/
https://www.ncbi.nlm.nih.gov/pubmed/26894863
http://dx.doi.org/10.18632/oncotarget.7436
work_keys_str_mv AT viudezantonio anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT carvalhofilipelf anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT malekizahra anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT zahurakmarianna anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT laherudaniel anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT starkalejandro anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT azadniloferz anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT wolfgangchristopherl anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT baylinstephen anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT hermanjamesg anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT dejesusacostaana anewimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT viudezantonio newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT carvalhofilipelf newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT malekizahra newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT zahurakmarianna newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT laherudaniel newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT starkalejandro newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT azadniloferz newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT wolfgangchristopherl newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT baylinstephen newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT hermanjamesg newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet
AT dejesusacostaana newimmunohistochemistryprognosticscoreipsforrecurrenceandsurvivalinresectedpancreaticneuroendocrinetumorspannet

Ejemplares similares